L1CAM and neoplasm: In our previous attempt to develop a therapeutic antibody with anti-tumor activity, we isolated a human mAb that cross-reacts with rodent L1CAM from a human naïve antibody library, and we then generated an affinity-matured version (Ab417) of this hit and validated its anti-tumor efficacy and mechanism of action in rodent models [31,32].